Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Depreciation & Amortization (CF) (2016 - 2025)

Kiora Pharmaceuticals' Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $10508.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 77.74% year-over-year to $10508.0; the TTM value through Dec 2025 reached $24801.0, up 29.14%, while the annual FY2025 figure was $24801.0, 29.14% up from the prior year.
  • Depreciation & Amortization (CF) reached $10508.0 in Q4 2025 per KPRX's latest filing, roughly flat from $10552.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $22477.0 in Q2 2023 to a low of $318.0 in Q1 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $8933.7, with a median of $10508.0 recorded in 2025.
  • The largest YoY upside for Depreciation & Amortization (CF) was 403.68% in 2025 against a maximum downside of 93.47% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $11036.0 in 2021, then fell by 2.38% to $10773.0 in 2022, then decreased by 26.34% to $7935.0 in 2023, then fell by 25.49% to $5912.0 in 2024, then soared by 77.74% to $10508.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Depreciation & Amortization (CF) are $10508.0 (Q4 2025), $10552.0 (Q3 2025), and $3423.0 (Q2 2025).